PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDS's Marketplace 2012 Trade Convention

SCHOFIELD, Wis., June 12, 2012 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) announced today that they will be attending NACDS's tradeshow, Marketplace 2012, being held in Denver, Colorado between June 23- 26, 2012.

In conjunction with the event, PuraMed BioScience is implementing a media blitz for LipiGesic® M, which has been clinically tested by leading US headache specialists and found to be a safe, highly effective, first-line therapy for treating migraine pain and its associated symptoms.

Attendance at the annual NACDS conference, will give PuraMed BioScience the opportunity to introduce LipiGesic M to over 230 retail companies that represent over 145,000 retail outlets. "We have already scheduled over 30 appointments with key wholesalers and retailers from all across the company," said Russ Mitchell, president and CEO of PuraMed BioScience.

"Now that we have established national distribution with our main retail partners, it is time to expand our distribution," said Mitchell. "The NACDS Marketplace 2012 is the best place to begin this process. There is no other trade event where we can get our clinically-tested Migraine treatment product in front of this many distribution opportunities at one time."

Coinciding with the NACDS Marketplace 2012 tradeshow, PuraMed BioScience has planned and is executing its most extensive advertising campaign to date.

The marketing blitz was developed to introduce consumers in the Denver region to the benefits, effectiveness and availability of clinically-tested LipiGesic M.

The eight-week media push, which will include newspaper, radio, television and in-store video displays, will begin in Denver, Colorado, but will also include areas around the region such as Colorado Springs, Cheyenne, Wyoming, and Albuquerque, New Mexico.

"We are testing this type of 'media-blitz' advertising in the Denver region to see if it can be then be used as a model to carry forward into other urban centers across the US," said Mitchell. "We have been working with our retail partner and have devoted resources to help them educate their pharmacists and their consumers about LipiGesic M."

The main message of the advertising campaign will be the effectiveness, speed and unique delivery system of LipiGesic M. Messages will use real-life testimonials and presentations by medical spokespersons to inform the public about the product.

LipiGesic M is a natural, homeopathic, gel that is administered sublingually (under the tongue). Best results are achieved when LipiGesic M is administered according to directions and migraine suffers do not eat or drink for 15 minutes after taking LipiGesic M.

Users often report that LipiGesic M relieves their migraine in minutes.

The clinical trial results published in the July 2011 issue of Headache: The Journal of Head and Face Pain, a top-tier medical publication, shows that LipiGesic M is an effective, first-line treatment for migraine when used at the first sign of headache. LipiGesic M has no known drug interactions, has an excellent safety profile, and does not produce rebound headache.

To promote LipiGesic M to the medical community, PuraMed BioScience has already sent sample kits to over 120 health professionals in the Denver region who have requested samples of LipiGesic M.

 "We timed this incentive to coincide with the NACDS convention so that if any attendees should visit stores in the region, they would see how our existing retail partners market our product," said Mitchell.

To learn more about the NACDS trade event, go to: http://www.nacdsmarketplace.org/

To learn more about this homeopathic migraine product and read the clinical study, visit www.LipiGesic.com.

About the Company:

PuraMed BioScience, Inc., engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic® M, which provides acute relief from migraine headaches; the company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. 

For more information on PuraMed BioScience, visit www.PuraMedBioScience.com, join the company's group page on Facebook by searching "PuraMed BioScience" and follow the company on Twitter at www.twitter.com/puramed.

Forward-Looking Statements:

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

SOURCE PuraMed BioScience, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED